Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
https://link.springer.com/content/pdf/10.1007/s40265-021-01654-3.pdf
Reference197 articles.
1. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7(1):99–108. https://doi.org/10.6004/jnccn.2009.0009.
2. Maloney A. A new paradigm. “Learn-Learn More”; dose-exposure-response at the center of drug development and regulatory approval. Clin Pharmacol Ther. 2017;102(6):942–50. https://doi.org/10.1002/cpt.710.
3. Mathijssen RH, Sparreboom A, Verweij J. Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol. 2014;11(5):272–81. https://doi.org/10.1038/nrclinonc.2014.40.
4. Rybak MJ, Le J, Lodise T, Levine D, Bradley J, Liu C, et al. Executive summary: therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. J Pediatr Infect Dis Soc. 2020;9(3):281–4. https://doi.org/10.1093/jpids/piaa057.
5. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02): e1. https://doi.org/10.1055/s-0037-1600991.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Reversibly “double locked” hydroxycamptothecin prodrug nanoparticles for targeted chemotherapy of lung cancer;Acta Biomaterialia;2023-08
2. Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer;Molecular Cancer;2022-10-06
3. Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib;Pharmaceutical Research;2022-03-29
4. Pharmacokinetically guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients;British Journal of Clinical Pharmacology;2022-03-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3